Novel Anti-Reductive Strategies for the Treatment of Heart Failure, Diabetes Mellitus and Degenerative Diseases
Though oxidative stress is widely implicated in pathogenic states including aging and heart failure, the role of reductive stress, which is defined as the abnormal increase of reducing equivalents (e.g., glutathione, NADPH), remains controversial. The present invention provides genetic, molecular, and biochemical evidence for showing the role of reductive stress in mammals, and proposes novel and, potentially personalized, therapeutic strategies to use anti-reductants for the treatment of human diseases such as heart failure, diabetes mellitus, and degenerative diseases. Anti-reductants are agents that assist in restoring homeostatic control for handling the byproducts of normal aerobic respiration such as reactive oxygen species (ROS) and reactive nitrogen species (RNS).
Cardiac hypertrophy and heart failure are major public health problems in western countries with over 20 billion dollars are spent on health care costs alone. The mouse models generated in this study are ideal for developing a commercial test used for diagnosis, monitoring and prevention of reductive stress in patients at high risk for cardiac hypertrophy, cardiomyopathy, and heart failure. Also, given prior extensive clinical studies on the bona fide molecular target for reductive stress that was identified in this study, human trials for new applications can proceed rapidly.
Stage of Development
A provisional patent application has been filed with the U.S. Patent and Trademark Office.
This technology is available for developmental research support or licensing under either exclusive or non-exclusive terms.
Rajasekaran Namakkal, Ivor Benjamin
Type of Offer:
« More Life Sciences Patents